End-of-day quote
Shenzhen S.E.
03:30:00 10/05/2024 am IST
|
5-day change
|
1st Jan Change
|
6.77
CNY
|
-4.38%
|
|
+1.35%
|
-33.37%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
5,282
|
5,223
|
4,241
|
8,242
|
6,419
|
4,854
|
Enterprise Value (EV)
1 |
4,436
|
4,433
|
3,566
|
7,784
|
6,160
|
4,810
|
P/E ratio
|
39.6
x
|
185
x
|
-32.3
x
|
-60.5
x
|
-33.2
x
|
-12.1
x
|
Yield
|
5.96%
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
6.55
x
|
7.9
x
|
9.97
x
|
14.1
x
|
11.7
x
|
13.3
x
|
EV / Revenue
|
5.5
x
|
6.7
x
|
8.39
x
|
13.3
x
|
11.2
x
|
13.2
x
|
EV / EBITDA
|
40.1
x
|
946
x
|
-23
x
|
-37.8
x
|
-30.4
x
|
-14
x
|
EV / FCF
|
14.6
x
|
11.8
x
|
-38.3
x
|
-51.8
x
|
-37
x
|
-30.2
x
|
FCF Yield
|
6.86%
|
8.47%
|
-2.61%
|
-1.93%
|
-2.7%
|
-3.31%
|
Price to Book
|
2.15
x
|
3.19
x
|
2.67
x
|
5.35
x
|
4.78
x
|
4.76
x
|
Nbr of stocks (in thousands)
|
4,76,705
|
4,69,653
|
4,69,653
|
4,69,653
|
4,71,988
|
4,77,773
|
Reference price
2 |
11.08
|
11.12
|
9.030
|
17.55
|
13.60
|
10.16
|
Announcement Date
|
04/03/19
|
16/03/20
|
19/04/21
|
18/04/22
|
20/03/23
|
25/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
806.1
|
661.5
|
425.2
|
584.3
|
549
|
364.2
|
EBITDA
1 |
110.8
|
4.685
|
-155.2
|
-205.9
|
-202.7
|
-342.7
|
EBIT
1 |
84.12
|
-25.48
|
-189.8
|
-239.5
|
-233.7
|
-373.6
|
Operating Margin
|
10.44%
|
-3.85%
|
-44.64%
|
-40.99%
|
-42.57%
|
-102.6%
|
Earnings before Tax (EBT)
1 |
151
|
20.15
|
-160.2
|
-213
|
-243.1
|
-366.4
|
Net income
1 |
134.1
|
27.3
|
-133
|
-137.4
|
-197
|
-398.9
|
Net margin
|
16.63%
|
4.13%
|
-31.28%
|
-23.52%
|
-35.89%
|
-109.53%
|
EPS
2 |
0.2800
|
0.0600
|
-0.2800
|
-0.2900
|
-0.4100
|
-0.8400
|
Free Cash Flow
1 |
304.2
|
375.2
|
-93.04
|
-150.3
|
-166.6
|
-159.2
|
FCF margin
|
37.74%
|
56.73%
|
-21.88%
|
-25.72%
|
-30.34%
|
-43.72%
|
FCF Conversion (EBITDA)
|
274.66%
|
8,008.62%
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
226.91%
|
1,374.52%
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
0.6600
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
04/03/19
|
16/03/20
|
19/04/21
|
18/04/22
|
20/03/23
|
25/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
846
|
790
|
675
|
459
|
259
|
44.2
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
304
|
375
|
-93
|
-150
|
-167
|
-159
|
ROE (net income / shareholders' equity)
|
5.74%
|
1.33%
|
-8.26%
|
-8.76%
|
-13.6%
|
-33.6%
|
ROA (Net income/ Total Assets)
|
1.95%
|
-0.69%
|
-6.38%
|
-8.13%
|
-8.36%
|
-15.6%
|
Assets
1 |
6,886
|
-3,973
|
2,085
|
1,690
|
2,358
|
2,563
|
Book Value Per Share
2 |
5.160
|
3.480
|
3.380
|
3.280
|
2.850
|
2.140
|
Cash Flow per Share
2 |
0.7700
|
0.7500
|
0.3000
|
0.1800
|
0.5600
|
0.1800
|
Capex
1 |
95.5
|
59.9
|
48.9
|
56.2
|
56.5
|
32.2
|
Capex / Sales
|
11.84%
|
9.06%
|
11.49%
|
9.62%
|
10.29%
|
8.83%
|
Announcement Date
|
04/03/19
|
16/03/20
|
19/04/21
|
18/04/22
|
20/03/23
|
25/03/24
|
|
1st Jan change
|
Capi.
|
---|
| -33.37% | 448M | | -2.61% | 89.08B | | +3.55% | 40.9B | | -14.40% | 32.25B | | +55.89% | 25.14B | | -15.96% | 15.39B | | -15.50% | 11.91B | | -41.29% | 11.89B | | -11.75% | 11.64B | | +7.87% | 9.03B |
Biopharmaceuticals
|